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Abstract
Introduction Non-ST-segment elevation acute coronary
syndromes (NSTE ACS) are highly prevalent in the United
States and globally, and are associated with significant
morbidity and mortality.
Discussion The key role of platelet-mediated thrombosis in
the pathogenesis of NSTE ACS is confirmed by the proven
clinical benefits of antiplatelet agents (aspirin and a P2Y12
adenosine diphosphate [ADP] receptor antagonist) in this
setting. Despite the documented advantages and broad use
of antiplatelet therapy, the long-term morbidity and mortal-
ity rates remain significant, and the bleeding risk remains
substantial. Residual risk can be attributed, at least in part,
to the fact that thrombosis continues in the presence of
current treatments because aspirin and P2Y12 ADP receptor
antagonists each block only one of multiple platelet
activation pathways, and thus do not impact other platelet
activation pathways, such as the one triggered by interac-
tion of thrombin with protease-activated receptor (PAR)-1,
thereby exposing patients to continued accumulation of
thrombotic events.
Conclusion These considerations suggest that novel thera-
pies with a different mechanism of action, when used in
combination with current antiplatelet agents, may provide
more comprehensive inhibition of platelet activation and
additional reductions in morbidity and mortality, potentially
without incremental bleeding risk.
Key words Non-ST-segmentelevationacutecoronary
syndromes.Antiplatelettherapy.PAR-1.Percutaneous
coronaryintervention.Bleeding
Introduction
Non-ST-segment elevation acute coronary syndromes
(NSTE ACS), which comprise unstable angina (UA) and
non-ST-segment elevation myocardial infarction (NSTEMI),
are associated with significant morbidity, mortality and
economic burden in the United States. Of the over 1.3
million unique annual hospitalizations for ACS in the United
States in 2006, over 800,000 were for myocardial infarction
(MI) (approximately two-thirds of these were NSTEMI) and
almost 540,000 were for UA [1]. In addition, over 150,000
Americans died from an MI in 2005 [1]. The primary
pathophysiological mechanism responsible for clinical
manifestations of NSTE ACS involves occlusion of coronary
arteries by platelet-rich thrombi, whose generation was
triggered in response to injury to vascular endothelium, such
as a rupture or erosion of an atherosclerotic plaque [2].
Platelet activation, a key step in platelet thrombus formation,
can be initiated by multiple agonists, such as thrombin,
thromboxane A2, adenosine diphosphate (ADP) and collagen
[3]; the goal of medical therapy is to prevent platelet-
mediated thrombosis and the resulting acute ischemic events.
The key role of platelet-mediated thrombosis in the
pathogenesis of NSTE ACS is confirmed by the proven
clinical benefits of antiplatelet agents in these patients [4–6].
However, despite the documented clinical efficacy of
antiplatelet therapy with aspirin and a P2Y12 ADP receptor
antagonist, the long-term morbidity and mortality associated
with NSTE ACS remains significant [5, 6], as these agents
each block only one of the multiple platelet activation
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DOI 10.1007/s10557-009-6204-5pathways leading to thrombotic events; they do not interfere
with the pathways stimulated by other platelet activators,
including thrombin, the most potent platelet agonist [7, 8].
The stimulatory effect of thrombin on platelet-mediated
thrombosis continues even in the presence of aspirin and a
P2Y12 ADP receptor antagonist, thereby potentially leading
tothromboticevents.Inclinicalpractice,theresidualischemic
risk in patients with NSTE ACS is often further exacerbated
by the underuse of antiplatelet agents in spite of their well-
documented benefits [9–11]. Apart from the substantial
residual risk for ischemic events, current oral antiplatelet
agents are also associated with increased bleeding risk.
These considerations underscore the need for more compre-
hensive prevention of platelet-mediated thrombosis and
associated ischemic events, ideally without an incremental
bleeding risk.
The aims of this review are to discuss the results and
clinical implications of key clinical trials with oral
antiplatelet agents in patients with NSTE ACS, as well as
to review the emerging evidence regarding the “net clinical
benefit” or the balance between bleeding and ischemic
events. In addition, this review will also address the current
management of NSTE ACS in US clinical practice, based
on the findings from the ACTION (NRMI/CRUSADE) and
GRACE registries, and the opportunities for improvements
in patient care.
Oral antiplatelet therapy: benefits and risks
Aspirin Aspirin inhibits the activity of the cyclooxygenase
(COX)-1 enzyme, thereby limiting the production of
thromboxane A2, an important platelet agonist implicated
in both pathologic thrombus formation and protective
hemostasis [3]. The efficacy of aspirin for treatment of
patients presenting with NSTE ACS and for secondary
prevention in patients with established atherothrombotic
disease has been demonstrated in several clinical trials [12–
14] and meta-analyses [4]. Aspirin is the foundation of
treatment recommendations for both acute and chronic
antiplatelet therapy in patients with NSTE ACS [15, 16].
However, residual morbidity and mortality and bleeding
risk remain substantial with aspirin. An observed inverse
relationship between aspirin dose and clinical benefit [3]
may be attributed to a dose-dependent increase in bleeding
risk (mainly gastrointestinal bleeding) [17]. It should be
noted that even low aspirin doses (≤100 mg) are associated
with increased bleeding rates compared with placebo [18].
However, the inverse relationship between aspirin dose and
clinical benefit may not rely solely on higher bleeding risk,
but also on a trend toward a lower anti-thrombotic benefit
at doses higher than 75–100 mg/day [19]. The lack of
additional cardiovascular benefit by increasing doses of
aspirin has been recently confirmed by results of the
CURRENT-OASIS 7 trial (discussed below) [20] and may
be attributed to a dose-dependent inhibition of prostacyclin
at higher doses of aspirin [21].
P2Y12 ADP receptor inhibitors These agents, including
clopidogrel, prasugrel and ticagrelor, bind to and inhibit the
activation of the platelet P2Y12 receptor by its physiological
ligand ADP, which is released from activated platelets, and
amplifies platelet activation and aggregation [3]. Clopidog-
rel is a thienopyridine prodrug that is converted into an
active compound by cytochrome P450 isoenzymes in the
liver [22]. Addition of clopidogrel to aspirin in patients
with NSTE ACS was demonstrated to reduce the risk of
adverse ischemic outcomes and to increase bleeding risk
versus aspirin alone in the CURE trial (Table 1)[ 6], as well
as in its substudy PCI-CURE in patients with NSTE ACS
who have undergone percutaneous coronary intervention
(PCI) [23]. On the basis of these findings, the addition of
clopidogrel to aspirin has become the standard of care for
patients with NSTE ACS, and its use in these patients is
recommended by both the American College of Cardiology
(ACC)/American Heart Association (AHA) [15] and Euro-
pean guidelines [16]. Furthermore, the benefits of adding
clopidogrel to aspirin have also been demonstrated in
patients with ST-segment elevation MI [24] and patients
undergoing elective PCI [25], as well as in patients with
atrial fibrillation who do not wish to or cannot take
anticoagulant warfarin [26]. The CHARISMA trial did not
demonstrate a significant benefit of clopidogrel plus aspirin
vs aspirin alone in the overall population of patients with
clinically documented atherothrombotic disease or multiple
risk factors [27]; however, a significant reduction in the
incidence of ischemic events with the combination of
clopidogrel and aspirin was evident in the secondary
prevention cohort (ie, in patients with prior MI, stroke or
symptomatic peripheral arterial disease) [28]. Most recently,
the CURRENT-OASIS 7 trial evaluated the efficacy and
safety of high-dose versus standard-dose clopidogrel in
patients with ACS [20]. Patients (n=25,087) assigned to
high-dose clopidogrel received a 600-mg loading dose and
150 mg once daily for seven days, followed by 75 mg once
daily until day 30. Patients in the standard clopidogrel arm
received a 300-mg loading dose, followed by 75 mg once
daily until 30 days. After day 30, all patients received
clopidogrel 75 mg once-daily. Patients were also randomized
to receive low-dose (75 to 100 mg per day) or high-dose
(300 to 325 mg per day) aspirin. In the overall study
population, there was no significant difference in the primary
endpoint (combined rate of death from CV causes, MI, and
stroke) between patients receiving the high-dose and the
standard-dose clopidogrel therapy (4.2% vs 4.4%; P=0.37)
[20] In patients who underwent PCI, however, the high-dose
490 Cardiovasc Drugs Ther (2009) 23:489–499clopidogrel regimen was associated with a 15% relative
reduction in risk of death from CV causes, MI, or stroke at
30 days versus the standard-dose regimen (3.9% versus
4.5%; P=0.036). No significant differences in efficacy were
observed between the high-dose and the standard-dose
clopidogrel arms in patients who did not undergo PCI. In
patients who underwent PCI, treatment with the high-dose
clopidogrel regimen was also associated with significant
reductions in stent thrombosis and MI at 30 days No
significant differences in TIMI major bleeding, fatal bleed-
ing, intracranial hemorrhage, or CABG-related bleeding
were observed between the two clopidogrel treatment arms.
As alluded to above, there was no significant difference in
the primary outcome in patients allocated high-dose versus
low-dose aspirin (4.2% vs 4.4%; P=0.47) [20]. Of note,
rates of TIMI major bleeding were also comparable between
the high-dose and low-dose aspirin groups (0.97% vs 1.03%;
P=0.71).
Several studies have documented variable responsiveness
of platelets to therapy with clopidogrel [29]. Although a
standardized definition and methodology for assessment of
responsiveness to antiplatelet therapy has not been estab-
lished, sufficient evidence supports the concept that persis-
tence of enhanced platelet reactivity despite the use of
clopidogrel is clinically relevant [30–33]. A correlation
between low level of inhibition of ADP-induced platelet
aggregation in response to clopidogrel and recurrence of
ischemic events has been documented in several studies in
patients with ACS and those undergoing PCI [31–33].
Although the mechanisms responsible for the variability
and low responsiveness to clopidogrel have not been fully
elucidated, recent analyses suggest that genetic polymor-
phisms of the cytochrome P (CYP) 450 enzymes can
significantly modulate individual response to clopidogrel
and are important determinants of prognosis [34–36]. A
study of patients with acute MI treated with clopidogrel
demonstrated that the carriers of the CYP2C19*2 allelic
variant (CYP2C19) had a significantly higher rate of
ischemic events (death, non-fatal MI, or urgent revascular-
ization) than non-carriers (10.9 events per 100 patient-years
vs 2.9 events per 100 patient-years, respectively; adjusted
hazard ratio: 5.38, P<0.0001) [34]. Similarly, in a French
registry of patients with acute MI treated with clopidogrel,
patients with any two loss-of-function CYP2C19 variants
had a significantly higher rate of death, non-fatal MI, or
stroke versus patients no loss-of-function alleles (21.5% vs.
13.3%; adjusted HR 1.98) [36]. The increased risk was
particularly prominent among patients undergoing PCI [36].
Additionally, in the TRITON trial (discussed below),
patients treated with clopidogrel who were carriers of at
least one reduced-function CYP2C19 allele had a signifi-
cantly higher rate of cardiovascular events than non-carriers
(12.1% vs. 8.0%, respectively; P=0.01) [35]. Other studies
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Cardiovasc Drugs Ther (2009) 23:489–499 491have suggested that co-administration of clopidogrel with
a proton pump inhibitor, particularly omeprazole,
decreases the antiplatelet effects and clinical benefit of
clopidogrel [37, 38], but the data supporting this association
are mixed [39].
The delayed onset of action and variable inhibition of
platelet aggregation with clopidogrel have prompted the
search for potentially more effective P2Y12 ADP receptor
antagonists. The first among these newer P2Y12 ADP
receptor antagonists is prasugrel, which is characterized by
a faster onset of action and more potent inhibition of ADP-
induced platelet aggregation as compared with clopidogrel
[40, 41]. The TRITON-TIMI 38 trial evaluated the efficacy
and safety of the combination of prasugrel plus aspirin
versus clopidogrel (300-mg loading dose plus 75-mg once-
daily maintenance dose) plus aspirin in patients with ACS
scheduled for PCI [5]. In TRITON, treatment with
prasugrel plus aspirin was associated with a significantly
lower rate of the combined end point of cardiovascular
death, non-fatal MI and non-fatal stroke versus treatment
with clopidogrel plus aspirin (Table 1)[ 5]. The net clinical
benefit (combined incidence of cardiovascular death, non-
fatal MI, non-fatal stroke and non-fatal Thrombolyis in
Myocardial Infarction [TIMI] major bleeding not related to
coronary artery bypass grafting [CABG] surgery) of
prasugrel was particularly pronounced in patients with
diabetes (hazard ratio [HR]: 0.74; p=0.001) and those
presenting with ST-segment elevation MI (HR: 0.81; p=
0.02), largely because these patient groups did not
experience an increase in TIMI major bleeding [42, 43].
The incidence of stent thrombosis was also substantially
lower in the prasugrel-plus-aspirin arm (Fig. 1)[ 44].
However, the residual risk for ischemic events with
prasugrel plus aspirin in TRITON-TIMI 38 remained
substantial (≈10% at 15 months; Table 1), and the risk of
bleeding (TIMI major, life-threatening, fatal, TIMI major
and minor, requiring transfusion and CABG surgery-
related) in the overall population was significantly higher
than with clopidogrel plus aspirin (Table 1)[ 5]. Further-
more, no net benefit of prasugrel plus aspirin over
clopidogrel plus aspirin was observed in patients aged
≥75 years with ACS (HR: 0.99; p=0.92) or those weighing
<60 kg (HR: 1.03; p=0.89), and a net clinical harm was
apparent in patients with prior stroke or transient ischemic
attack (TIA) (HR: 1.54; p=0.04) [5], primarily due to
higher rates of bleeding with prasugrel plus aspirin than
with clopidogrel plus aspirin in these patient groups. These
results suggest that the selection of a P2Y12 ADP receptor
antagonist should take into account not only the greater
pharmacological potency of prasugrel versus clopidogrel,
but also the increased risk for bleeding with prasugrel as
compared with clopidogrel. The net harm observed in
patients with stroke or TIA suggests that prasugrel should
be avoided in this patient group. Likewise, patients at
higher bleeding risk, such as the elderly or those with low
body weight, may not derive a net benefit from prasugrel. It
is important to note that consideration of the use of the 5-
mg maintenance dose of prasugrel in patients weighing
<60 kg, as described in the US prescribing information for
prasugrel [45], is entirely based on pharmacokinetic
modeling and is not supported by any clinical evidence.
In selected patients (ie, patients with diabetes or those with
STEMI) with ACS undergoing PCI, the combination of
prasugrel plus aspirin may provide greater protection
against ischemic events than the combination of clopidogrel
plus aspirin, although even in these patients the residual
risk for ischemic events with prasugrel plus aspirin
remained substantial [42, 43]. On the basis of these results,
prasugrel has recently been approved in Europe and in the
United States, although the pattern of its use in clinical
practice remains to be seen.
In addition to prasugrel, ticagrelor (AZD 6140), a novel
non-thienopyridine P2Y12 ADP receptor antagonist, has also
demonstrated a faster onset of action, more potent inhibition
of ADP-induced platelet aggregation than clopidogrel, as
well as more rapid reversal of inhibition of ADP-induced
Fig. 1 Incidence of stent
thrombosis over 15 months in
patients receiving prasugrel plus
aspirin versus clopidogrel plus
aspirin in the TRITON-TIMI 38
trial [44]. Reproduced with
permission
492 Cardiovasc Drugs Ther (2009) 23:489–499platelet activation and aggregation than clopidogrel [22].
Unlike clopidogrel or prasugrel, ticagrelor is not a prodrug
and does not require metabolic conversion into an active
metabolite [22]. These properties suggest that ticagrelor may
be an attractive alternative to clopidogrel, especially in
clinical situations where rapid inhibition of platelet aggrega-
tion or its quick reversal may be required. The efficacy and
safety of 1-year treatment with ticagrelor (plus aspirin versus
clopidogrel plus aspirin was recently reported in patients
with ACS in the phase 3 PLATO trial [46]( T a b l e1). Patients
receiving ticagrelor plus aspirin experienced a significant
reduction in the incidence of the composite endpoint of first
occurrence of CV death, MI, or stroke versus patients
receiving clopidogrel plus aspirin (Table 1). Of note, the rate
of all-cause death was 22% lower with ticagrelor versus
clopidogrel (P<0.001). There was no significant difference
in rates of major bleeding between the treatment arms
(Table 1). Rates of other adverse events were higher with
ticagrelor versus clopidogrel: dyspnea (13.8% versus 7.8%;
P<0.001), syncope (1.1% versus 0.8%; P=0.08), ventricular
pauses ≥3 s during the first week of treatment (5.8% versus
3.6%; P=0.01) and increase in serum uric acid and serum
creatinine at 1 month and 1 year (P<0.001 for each
comparison]) [46]. It is important to note that ticagrelor is
administered twice daily; in clinical practice, the need for
twice-daily dosing may increase the risk for ischemic events
in patients who are not fully compliant with the prescribed
therapy.
Even in the presence of dual antiplatelet therapy with
aspirin and a P2Y12 ADP receptor antagonist (clopidogrel,
prasugrel or ticagrelor), the risk for morbidity and mortality
remains substantial in patients with NSTE ACS, as well as
in those with ST-segment-elevation MI, atrial fibrillation, or
a history of prior atherothrombotic disease, and in patients
scheduled for PCI. This residual risk can be attributed to the
fact that multiple pathways contribute to platelet activation,
and aspirin and P2Y12 ADP receptor antagonists each
inhibit only one of these pathways (the thromboxane A2
and ADP pathways, respectively). The lack of an inhibitory
effect of current therapies on other platelet activation
pathways allows continued platelet reactivity in the pres-
ence of potent agonists, such as thrombin, thereby
increasing the risk for recurrent thrombotic/ischemic events,
including death. When used in combination with the current
standard-of-care therapies, new agents that target pathways
that are not affected by aspirin or P2Y12 ADP receptor
antagonists may provide complementary and more compre-
hensive inhibition of platelet activation, and thereby
contribute to greater inhibition of platelet-mediated throm-
bosis and incremental reductions in ischemic events. Apart
from the residual ischemic risk, dual antiplatelet therapy
with aspirin and a P2Y12 ADP receptor antagonist is also
associated with an increased risk of bleeding, because these
agents interfere with the thromboxane A2 and ADP platelet
activation pathways that are essential for normal hemostasis
[3]. These considerations underscore the need for novel
antiplatelet agents that provide more comprehensive platelet
inhibition without interfering with platelet activation path-
ways critical for hemostasis, for greater protection against
thrombotic events without an incremental bleeding risk.
PAR-1 (thrombin) receptor antagonists PAR-1 is the prin-
cipal receptor for thrombin on human platelets [47].
Interaction of thrombin, the most potent platelet agonist,
with PAR-1 promotes platelet shape change and granule
secretion, as well as other processes leading to platelet
activation [47]. Preclinical observations indicate that inhi-
bition or genetic inactivation of PAR-1 selectively interferes
with platelet activation mediated by thrombin and with
platelet deposition into an occlusive thrombus, but not with
thrombin-mediated fibrin generation or initial platelet
deposition that is important for healing in response to
vascular injury [48–50]. These results suggest that platelet
activation mediated by PAR-1 may be critical for thrombo-
sis but may not be necessary for hemostasis. PAR-1
inhibitors (or thrombin receptor antagonists [TRAs]) repre-
sent a novel class of antiplatelet agents. Currently, two
PAR-1 antagonists are in clinical development: E-5555 and
SCH 530348. When used in combination with the current
standard-of-care antiplatelet therapy (aspirin alone or dual
therapy with aspirin and a P2Y12 ADP receptor antagonist),
a PAR-1 inhibitor offers more comprehensive platelet
inhibition and potentially an incremental reduction in
ischemic events, possibly without a risk of increased
bleeding.
E-5555 is an orally active, potent PAR-1 antagonist that
has demonstrated antiplatelet effects without increasing
bleeding times in preclinical studies [51, 52]. Serebruany et
al. evaluated the in vitro effects of E-5555 on platelet
aggregation and biomarker expression in blood from
healthy volunteers (n=10), patients with documented
coronary artery disease (CAD) treated with aspirin (n=
10), and patients with documented CAD who were treated
with aspirin plus clopidogrel (n=10) [53]. Complete
inhibition of TRAP-induced platelet aggregation was
observed at all concentrations of E-5555 evaluated (20,
50, and 100 ng/ml), including the lowest dose [53]. Modest
inhibition of platelet aggregation induced by ADP and
collagen was observed. Four ongoing Phase 2 trials are
evaluating the safety and tolerability of daily, oral admin-
istration of E-5555 (50 mg, 100 mg or 200 mg) in patients
with CAD or NSTE ACS in the US and Japan [54–57].
SCH 530348 is the first oral PAR-1 inhibitor in phase 3
clinical development [58]. The phase 2 TRA-PCI trial
evaluated the safety and efficacy of SCH 530348 (admin-
istered as either a 10-, 20-, or 40-mg loading dose followed
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for 59 days) used in combination with standard oral
antiplatelet therapy (aspirin and clopidogrel) and an
antithrombin agent (heparin or bivalirudin) versus placebo
in patients with planned non-urgent PCI [59]. Based on the
recommendation of the safety review committee, enroll-
ment of the prespecified 1,600 patients was reduced
because of low TIMI major and minor bleeding rates.
TRA-PCI randomized a total of 1,030 patients, of which
573 subsequently underwent PCI as planned (primary PCI
cohort), whereas the remaining patients either underwent
CABG surgery (n=76) or were managed medically (n=
381) [59]. Although the study may be underpowered for
safety results, rates of clinically significant bleeding were
low overall in TRA-PCI. Administration of SCH 530348 in
combination with standard therapy was not associated with
increased rates of TIMI major or minor bleeding, the
primary endpoint, compared with standard therapy alone in
the primary PCI cohort (2.8% vs 3.3%; P=0.77) [59]. None
of the patients treated with the combination of the highest
loading and maintenance doses of SCH 530348 (40-mg
loading dose plus 2.5-mg maintenance dose) experienced
TIMI major bleeding, although rates of overall bleeding,
TIMI minor bleeding and non-TIMI bleeding were numer-
ically higher with SCH 530348. The rate of discontinua-
tions due to non-TIMI bleeding in the primary cohort were
similar in the combined SCH 530348 and placebo arms
(1.4% and 1.3%, respectively) [59]. The rate of TIMI major
or minor bleeding did not differ significantly between
patients allocated SCH 530348 versus placebo who
underwent CABG surgery (90% vs 79%) [59]. No clear
dose-response relationship for post-operative bleeding was
evident in surgical patients. More patients who underwent
CABG and received SCH 530348 versus placebo needed
transfusions; however the proportion of patients who
needed ≥2 units of packed red blood cells did not differ
between groups. Among patients who were managed
medically, TIMI major/minor bleeding was observed in 3
patients allocated SCH 530348 and zero patients allocated
placebo [59]. Although not powered to detect differences in
efficacy endpoints, a lower incidence of ischemic events,
specifically MI, was observed in patients allocated SCH
530348 [59]. In this study, the most rapid onset of action
(as measured by inhibition of thrombin receptor agonist
peptide [TRAP]-induced platelet aggregation) was provided
by the 40-mg loading dose of SCH 530348, whereas the
2.5-mg once-daily maintenance dose of SCH 530348
subsequently selected for phase 3 trials sustained complete
(>80%) inhibition of TRAP-induced platelet aggregation
over the 60-day treatment period [59]. Importantly, SCH
530348 selectively inhibits platelet aggregation induced by
TRAP but does not interfere with the aggregation induced
by other platelet agonists, such as arachidonic acid, ADP, or
collagen [60]. A separate phase 2 trial in Japanese patients
with NSTE ACS scheduled for PCI also demonstrated that
the addition of SCH 530348 to the standard-of-care therapy
(aspirin plus ticlopidine) did not result in increased
b l e e d i n gr i s ka n dw a sa s s o c i a t e dw i t has i g n i f i c a n t
reduction in periprocedural MI [61]. These results suggest
that the use of SCH 530348 in combination with standard
antiplatelet therapy (aspirin with or without a P2Y12 ADP
receptor antagonist) may provide incremental reductions in
ischemic events, potentially without an increased risk of
bleeding. Two large ongoing phase 3 trials are evaluating
the benefits and bleeding risks associated with the addition
of SCH 530348 to the standard-of-care therapy (aspirin
alone or aspirin plus a P2Y12 ADP receptor inhibitor) in
patients presenting with NSTE ACS (N≈10,000; Clinical-
Trials.gov Identifier: NCT00527943) and in secondary
prevention (N≈25,000 patients; ClinicalTrials.gov Identifier:
NCT00526474).
Relationship between bleeding and ischemic events
An increase in bleeding risk in patients treated with aspirin
and P2Y12 ADP receptor antagonists has been well
recognized, and several recent studies suggest that bleeding
and blood transfusions may represent independent predic-
tors of short- and long-term mortality in patients with ACS
and in those undergoing PCI [62–66]. For example, a 2004
report by Rao and colleagues evaluated the correlation of
blood transfusions and morbidity and mortality in over
24,000 patients with ACS, demonstrating that transfusions
were a powerful predictor of 30-day mortality (HR: 3.94;
95% confidence interval [CI] 3.26–4.75; p<0.001) and 30-
day death/MI (HR: 2.92; 95% CI 2.55–3.35; p<0.001) [65].
Similarly, the risk for 30-day and 6-month mortality among
over 26,000 patients with NSTE ACS was shown to
increase proportionally with greater severity of bleeding
[66]. These observations were further confirmed by a
pooled analysis of the OASIS registry and the OASIS-2
and CURE trials, which involved over 34,000 patients with
NSTE ACS [62]. This study demonstrated that major
bleeding was associated with a fivefold increase in the risk
of mortality at 30 days (Fig. 2a)[ 62], and that the risk of
death over the 6-month follow-up increased in proportion to
the bleeding severity (Fig. 2b)[ 62]. In addition to the
mortality increase, major bleeding was also associated with
a significantly increased risk of MI (HR: 4.44; 95% CI
3.16–6.24; p<0.0001) and stroke (HR: 6.46; 95% CI 3.54–
11.79; p<0.0001) within 30 days [62]. In the ACUITY
trial, patients with NSTE ACS who experienced major
bleeding had significantly higher 30-day incidences of
death, composite ischemia and stent thrombosis than patients
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major bleeding was the strongest independent predictor of
30-day mortality (HR: 7.55; 95% CI 4.68–12.18; p<0.0001)
[63]. Additionally, a pooled analysis of 4 ISAR trials in
patients undergoing PCI (ISAR-REACT, ISAR-SWEET,
ISAR-SMART 2 and ISAR-REACT 2) demonstrated that
bleeding within 30 days was an independent predictor of 1-
year mortality (HR: 2.96; 95% CI 1.96–4.48; p<0.001)[64].
Of note, the predictive value of bleeding within 30 days for
1-year mortality was comparable to that of MI within 30 days
(HR: 2.29; 95% CI 1.52–3.46; p< 0 . 0 0 1 )o ru r g e n tr e v a s c u -
larization within 30 days (HR: 2.49; 95% CI 1.16–5.35; p=
0.019) [64]. Collectively, these results suggest that bleeding
is a significant risk factor for death and ischemic events. The
mechanisms linking bleeding and blood transfusions to
increased mortality in patients with ACS and patients
undergoing PCI are incompletely understood but likely
involve multiple factors, including the location and intensity
of bleeding, impaired oxygen delivery, as well as discontin-
uation of antiplatelet therapy [67]. Regardless of the
mechanisms and factors that may contribute to the increased
risk of mortality associated with bleeding and blood trans-
fusions, it is clear that the approaches designed to minimize
the bleeding risk may also result in lower rates of ischemic
events and thereby improve overall patient outcomes.
Use of antiplatelet therapy in clinical practice: insights
from registries
Continuous evaluations of management of patients with
NSTE ACS in the United States in the CRUSADE registry
from 2002 to 2004 have demonstrated significant improve-
ments in use of medications both in the acute setting
(antiplatelet agents, anticoagulants, glycoprotein IIb/IIIa
receptor inhibitors and beta-blockers) and in the discharge
setting (antiplatelet agents, lipid-lowering agents,
angiotensin-converting enzyme inhibitors) [11]. However,
use of many therapies was suboptimal, and there was a
clear need for greater implementation of the ACC/AHA
guidelines’ recommendations [11]. CRUSADE has also
documented significantly lower use of evidence-based
therapies in the elderly, women, minority populations, and
patients without private insurance [68–70]. More recently,
the ACTION registry reported that clopidogrel was used in
only 60% of patients with NSTEMI in the acute setting and
in 74% of patients with NSTEMI at discharge during 2008
[71]. Differences in clopidogrel utilization have also been
noted based on management strategy [70, 71]. The latest
available data from ACTION for the year 2008 document
that clopidogrel was used among patients with NSTEMI at
the time of hospital discharge in 97% of those who
underwent PCI, but in only 55% of those who were
medically managed,and inonly28% of those who underwent
CABG, even though they were admitted to the hospital with
an ACS [71]. Importantly, lack of early clopidogrel use was
Fig. 2 a Relationship between major bleeding and mortality in a
meta-analysis of 34,146 patients with NSTE ACS in the OASIS-1,
OASIS-2 and CURE trials during the first 30 days (HR: 5.37; 95% CI
3.97–7.26; p<0.0001) [62]. b Relationship between bleeding severity
and the risk of death: Kaplan-Meier estimates of mortality among
patients who developed no, minor, major (excluding life-threatening)
or life-threatening bleeding in the CURE trial (p for trend = 0.0009)
[62]. Reproduced with permission
3.5
2.3
5.4
2
8.1
0.7
5.3
3
7.6
2.5
11
1
0
4
8
12
Death Post-
admission
MI
Death or MI Cardiogenic
shock
Heart failure Stroke
Clopidogrel within 24 h (n=35,880)
No clopidogrel within 24 h (n=57,165) 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
e
v
e
n
t
 
(
%
)
*
*
*
*
*
*
*P<0.01 vs clopidogrel.
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other adverse outcomes compared with early initiation of
clopidogrel in CRUSADE (Fig. 3)[ 9].
The global GRACE registry of over 27,000 patients
with NSTE ACS in 14 countries has reported significant
reductions in clinical events and increased utilization of
medical therapies and PCI between 1999–2000 and
2005 [10]. These improvements included significant
decreases in the rates of in-hospital death (2.9% in
1999–2000 versus 2.2% in 2005; p=0.02) and 6-month
mortality (4.9% in 1999–2000 versus 3.3% in 2005; p=
0.04) [10]. The rates of in-hospital congestive heart failure
or pulmonary edema, MI, cardiogenic shock and 6-month
stroke were also significantly lower (all p<0.05) in 2005
than in 1999–2000, while the in-hospital rates of stroke
and 6-month rates of MI did not differ significantly [10].
These reductions in clinical events may be attributed, at
least in part, to considerable increases in adherence to
guidelines-based use of thienopyridines and lipid-lowering
agents, as recommended by the US and European
guidelines [10].
Registry data have documented considerable advances in
patient care and improved clinical outcomes. Nevertheless,
in-hospital mortality rates remain substantial in the United
States (4.1% in patients with NSTEMI in ACTION) and
globally (2.2% in patients with NSTE ACS in GRACE)
[10, 71]. Despite the ACC/AHA guidelines’ recommenda-
tions [15], clopidogrel initiation is often postponed until
after diagnostic catheterization and withheld at the time of
discharge in patients who are managed medically and those
who undergo surgical revascularization. Thus, there is
considerable room for greater adherence to the guidelines’
recommendations for the use of oral antiplatelet therapy
among patients with NSTE ACS in the acute and
particularly in the chronic setting, which can lead to
improved patient outcomes. At the same time, bleeding
and blood transfusions, which are associated with increased
mortality risk, remain a frequent complication in patients
with NSTE ACS. For example, major bleeding and red
blood cell transfusion occurred during 2008 in the
ACTION registry in 12% and 15% of patients with
NSTEMI, respectively [71], while GRACE reported major
bleeding in 4.7% of patients with NSTEMI and 2.3% of
patients with UA [72]. Unadjusted in-hospital death rates in
GRACE in patients with NSTEMI with major bleeding
versus no bleeding were 15.3% versus 5.3% (p<0.001)
[72]. These considerations suggest that the clinical benefits
of greater use of current oral antiplatelet therapies recom-
mended by the guidelines may be partially offset by the
increased risk for bleeding or blood transfusions, and
thereby underscore a critical need for novel therapies that
reduce the risk of ischemic events without exacerbating the
risk of bleeding complications.
Conclusions
Clinical trials and registry data have documented clear
beneficial effects of current oral antiplatelet agents (aspirin
and P2Y12 ADP receptor inhibitors) on ischemic outcomes
in patients with NSTE ACS. However, despite the proven
clinical efficacy of these agents, residual morbidity and
mortality remain substantial even in patients receiving dual
antiplatelet therapy. This residual ischemic risk may be
explained by the fact that these agents interfere only with
the thromboxane A2 and ADP platelet activation pathways
and do not block platelet-mediated thrombosis stimulated
by other platelet activators (such as thrombin), allowing the
accumulation of ischemic events. In addition to a high
residual risk for ischemic events, aspirin and P2Y12 ADP
receptor antagonists are associated with increased bleeding
risk, which can be attributed to the inhibitory effect of these
agents on pathways essential for hemostasis. Novel thera-
peutic approaches such as the PAR-1 inhibitors, targeting
platelet activation pathways not affected by current anti-
platelet agents, represent an attractive strategy to reduce the
residual ischemic risk in patients with NSTE ACS, possibly
without exacerbating the risk of bleeding. In addition to
novel therapeutic approaches, improvements in clinical
outcomes in standard practice can also be achieved through
the greater use of currently available antiplatelet agents
with proven efficacy, such as aspirin and clopidogrel,
particularly in patients who are managed without PCI.
The benefits of increased use of currently recommended
oral antiplatelet agents, though, should be balanced against
the increased risk for bleeding complications. The avail-
ability of oral antiplatelet agents with a more favorable
benefit-to-risk profile than the currently available therapies
would represent a major advance in the treatment of
patients with NSTE ACS.
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